REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction

Dermatologic Surgery ◽

10.1097/dss.0000000000000578 ◽

2016 ◽

Vol 42 (1) ◽

pp. 38-49 ◽

Author(s):

Derek H. Jones ◽

Jean Carruthers ◽

John H. Joseph ◽

Valerie D. Callender ◽

Patricia Walker ◽

...

Keyword(s):

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Injectable Drug ◽

Fat Reduction ◽

Download Full-text

A Pooled Analysis of the Safety and Efficacy Results of the Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 3 REFINE-1 and REFINE-2 Trials of ATX-101, a Submental Contouring Injectable Drug for the Reduction of Submental Fat

Plastic & Reconstructive Surgery ◽

10.1097/01.prs.0000455489.32830.4a ◽

2014 ◽

Vol 134 ◽

pp. 123 ◽

Author(s):

Steven H. Dayan ◽

Derek H. Jones ◽

Jean Carruthers ◽

Shannon Humphrey ◽

Fredric S. Brandt ◽

...

Keyword(s):

Pooled Analysis ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Injectable Drug ◽

Download Full-text

IP 1184. ZX008 (Fenfluramine) in Dravet’s Syndrome: First Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

10.1055/s-0038-1676032 ◽

2018 ◽

Author(s):

Tilman Polster ◽

Lieven Lagae ◽

Joseph Sullivan ◽

Ulrich Brandl ◽

Arne Herting ◽

...

Keyword(s):

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Analysis of adverse events in adult patients with acromegaly receiving oral octreotide capsules: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study

Endocrine Abstracts ◽

10.1530/endoabs.70.aep613 ◽

2020 ◽

Author(s):

Artak Labadzhyan ◽

Susan Samson ◽

Lisa Nachtigall ◽

Maria Fleseriu ◽

Mark E Molitch ◽

...

Keyword(s):

Adverse Events ◽

Adult Patients ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Withdrawal from long-acting somatostatin receptor ligand injections in adult patients with acromegaly: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study

Endocrine Abstracts ◽

10.1530/endoabs.70.aep668 ◽

2020 ◽

Author(s):

Lisa Nachtigall ◽

Susan Samson ◽

Maria Fleseriu ◽

Marek Bolanowski ◽

Molitch Mark E ◽

...

Keyword(s):

Somatostatin Receptor ◽

Adult Patients ◽

Phase 3 ◽

Double Blind ◽

Receptor Ligand ◽

Double Blind Placebo ◽

Long Acting ◽

Somatostatin Receptor Ligand

Download Full-text

Faculty Opinions recommendation of Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13198963.14726480 ◽

2011 ◽

Author(s):

Luciana Mascia ◽

Ilaria Mastromauro

Keyword(s):

Subarachnoid Haemorrhage ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Aneurysmal Subarachnoid Haemorrhage ◽

Endothelin Receptor ◽

Surgical Clipping ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020575.793481147 ◽

2013 ◽

Author(s):

J Michael Kilby

Keyword(s):

Hiv Infection ◽

Injecting Drug Users ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Antiretroviral Prophylaxis

Download Full-text

Faculty Opinions recommendation of Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020575.793481120 ◽

2013 ◽

Author(s):

Eric Daar

Keyword(s):

Hiv Infection ◽

Injecting Drug Users ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Antiretroviral Prophylaxis

Download Full-text

Faculty Opinions recommendation of Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718355395.793494247 ◽

2014 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725433886.793507009 ◽

2015 ◽

Author(s):

Adam Farmer

Keyword(s):

Chronic Constipation ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725403083.793507191 ◽

2015 ◽

Author(s):

Greg Bociek

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Autologous Stem Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Risk Of Relapse

Download Full-text